GLP-1 Drugs and Migraine: Liraglutide, Semaglutide and Tirzepatide Evidence

GLP-1 drugs are not approved for migraine, and no randomized trial has tested one for it. The early signals point toward fewer migraines rather than more. In a 31-patient Italian pilot, people with obesity and hard-to-treat migraine went from about 20 headache days a month to about 11 on liraglutide, with almost no weight change.^[6] In Denmark, people who started semaglutide for weight used slightly fewer triptans over the next year.^[8] Headache itself is a listed side effect, though in the trials it ran close to placebo rates.^[1][2] A few people report migraines getting worse.^[11]

What the labels record

None of the obesity labels lists migraine by name. They report headache, and the gap from placebo is small.

Saxenda’s one-point gap and Zepbound’s absence from the table suggest most headaches reported on these drugs would have happened anyway. The headache article explains the likely mechanisms, chiefly dehydration from nausea and eating less, and what to do about them, and the water intake calculator sets a daily fluid target.

Why migraine and weight are linked

Obesity raises the risk of migraine. A 2017 meta-analysis of 12 studies with almost 289,000 people found 27% higher odds of migraine with obesity than at normal weight, after adjusting for age and sex.^[4] A 2020 meta-analysis of 10 weight-loss studies in 473 people with obesity found that losing weight, by surgery or by diet and behavior change, reduced how often migraines came, how bad they were and how long they lasted. The improvement did not track how much weight people lost.^[5]

That second finding is why the GLP-1 question is hard to answer. A drug that causes weight loss would be expected to help some migraines through weight loss alone. The interesting question is whether these drugs act on migraine directly, and the studies so far were not built to separate the two cleanly.

The studies in migraine

The liraglutide pilot

Researchers at the University of Naples Federico II gave liraglutide 1.2 mg daily, a dose used in diabetes, to 31 adults with a BMI over 30 whose high-frequency or chronic migraine had not responded to at least two preventive treatments. They excluded anyone with signs that suggested idiopathic intracranial hypertension, such as swelling of the optic nerve or a pulsing ringing in the ears. Over 12 weeks, headache days fell from an average of 19.8 a month to 10.7, while BMI went from 34.0 to 33.9, a change that was not significant and did not predict who improved.^[6]

The authors suggest the drug may work by lowering pressure inside the skull, the mechanism behind the intracranial hypertension trial described in the headache article.^[6][13] The study had no placebo group, so it cannot show how much of the drop the drug caused. Two of the authors had received speaking fees from Eli Lilly.^[6]

Tirzepatide and semaglutide

Headache specialists in Washington, DC, reported two patients whose migraines became less frequent after starting tirzepatide, and wrote that weight loss in both was a significant confounder.^[7] The Danish registry study followed every adult who started semaglutide for weight between December 2022 and December 2024 and found triptan use, the main class of migraine attack medicine, about 7% lower after a year than the earlier trend predicted. The drop was in women, not men, and was largest in people aged 18 to 35 and those who had used migraine preventives before.^[8] Two of its authors work for Novo Nordisk.^[8]

A large US health-record study of semaglutide in type 2 diabetes looked at migraine as one of 22 brain-related outcomes. New migraine diagnoses in the following year were no more and no less common than on sitagliptin, empagliflozin or glipizide; a secondary analysis counting any migraine diagnosis found a 20% higher rate than on glipizide only.^[9]

Can a GLP-1 make migraine worse?

GLP-1 itself does not appear to trigger headache the way some migraine-provoking substances do. In a Copenhagen trial, 21 healthy volunteers received an infusion of GLP-1 and, on another day, placebo; headache was no more common after GLP-1 (10 people against 7), and blood flow in the brain’s arteries did not change.^[10] No one in that study had migraine, so it does not settle what happens in people who do.

There are individual reports of worsening. One published case describes a man in his early fifties with hemiplegic migraine, a rare form that causes temporary weakness on one side, whose attacks went from once or twice a year to near-daily during 60 days on liraglutide, and stopped when he came off it.^[11] A single case cannot show cause, but it is a reason to report a change in migraine pattern rather than assume it is the usual early side effect. The nausea, smaller meals and lower fluid intake of the first weeks can bring on headaches of their own; how long side effects last shows when those usually ease.

What is still missing

A 2024 systematic review of GLP-1 drugs across headache and pain found the migraine evidence was mainly from animal and mechanism studies.^[12] As of October 2026, ClinicalTrials.gov lists no trial of semaglutide, tirzepatide, liraglutide, exenatide or dulaglutide for migraine. The closest is a placebo-controlled trial of tirzepatide in idiopathic intracranial hypertension at Duke University, with about 60 participants planned and Eli Lilly as a collaborator, which began recruiting in August 2026.^[14]

Migraine prevention has treatments with randomized evidence. The American Headache Society’s 2024 position statement names therapies that target CGRP, a signaling molecule central to migraine, as a first-line preventive option.^[15] If you already take migraine medicine, the drug interaction checker shows known interactions with GLP-1 drugs. The Danish triptan drop was seen only in women, and side effects in women vs men covers the other effects that differ by sex.